实体癌和血液癌中RORing嵌合抗原受体T细胞：相同却又不同
RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
作者信息
Kobold Sebastian
机构信息
Division of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
German Cancer Consortium (DKTK), A Partnership Between LMU Hospital and DKFZ Heidelberg, Munich, Germany.
出版信息
Clin Cancer Res. 2025 Feb 3;31(3):437-438. doi: 10.1158/1078-0432.CCR-24-3688.
Abstract
A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
摘要
最近的一项I期临床研究对慢性淋巴细胞白血病、非小细胞肺癌和三阴性乳腺癌患者进行了抗ROR1嵌合抗原受体（CAR）T细胞测试。该产品可以安全给药，在慢性淋巴细胞白血病中有活性，但在非小细胞肺癌和三阴性乳腺癌中的活性较低。见耶格尔 - 鲁克施图尔等人的相关文章，第503页。
相似文献
1
RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.实体癌和血液癌中RORing嵌合抗原受体T细胞：相同却又不同
Clin Cancer Res. 2025 Feb 3;31(3):437-438. doi: 10.1158/1078-0432.CCR-24-3688.
2
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.ROR1特异性嵌合抗原受体T细胞在晚期造血和上皮恶性肿瘤中的I期研究。
Clin Cancer Res. 2025 Feb 3;31(3):503-514. doi: 10.1158/1078-0432.CCR-24-2172.
3
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造：创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
4
Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.双特异性抗体和自体嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤。
Mol Ther. 2024 Aug 7;32(8):2444-2460. doi: 10.1016/j.ymthe.2024.05.039. Epub 2024 May 31.
5
The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties.对健康组织产生反应的风险：新型嵌合抗原受体需要针对被忽视的结合特性进行检测。
Mol Ther. 2025 Jun 4;33(6):2328-2329. doi: 10.1016/j.ymthe.2024.12.035. Epub 2025 Jan 15.
6
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.嵌合抗原受体 (CAR) T 疗法治疗血液系统恶性肿瘤：临床观点与意义。
J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5.
7
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology.血液肿瘤学中除CD19和BCMA之外的新型嵌合抗原受体T细胞（CAR-T）疗法的未来展望
Front Immunol. 2025 Jul 14;16:1592377. doi: 10.3389/fimmu.2025.1592377. eCollection 2025.
8
Allogeneic CART progress: platforms, current progress and limitations.同种异体嵌合抗原受体T细胞疗法的进展：平台、当前进展及局限性
Front Immunol. 2025 Jun 12;16:1557157. doi: 10.3389/fimmu.2025.1557157. eCollection 2025.
9
Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?奥贝卡他基因自体白细胞介素，一种用于复发/难治性B细胞急性淋巴细胞白血病的新型CD19导向嵌合抗原受体T细胞疗法：降低毒性和T细胞耗竭的未来希望？
Expert Rev Hematol. 2025 Jun 23. doi: 10.1080/17474086.2025.2523551.
10
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.慢性淋巴细胞白血病患者来源的 CD19 嵌合抗原受体 T 细胞表现出升高的 IFN-γ 产生谱。
J Immunother. 2018 Feb/Mar;41(2):73-83. doi: 10.1097/CJI.0000000000000193.
本文引用的文献
1
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.ROR1特异性嵌合抗原受体T细胞在晚期造血和上皮恶性肿瘤中的I期研究。
Clin Cancer Res. 2025 Feb 3;31(3):503-514. doi: 10.1158/1078-0432.CCR-24-2172.
2
Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control.嵌合抗原受体 T 细胞活性控制的机制和策略。
Int J Cancer. 2023 Nov 15;153(10):1706-1725. doi: 10.1002/ijc.34635. Epub 2023 Jun 23.
3
Migratory Engineering of T Cells for Cancer Therapy.用于癌症治疗的T细胞迁移工程
Vaccines (Basel). 2022 Oct 31;10(11):1845. doi: 10.3390/vaccines10111845.
4
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.嵌合抗原受体 T 细胞疗法的免疫原性：证据、机制与缓解策略。
Front Immunol. 2022 May 23;13:886546. doi: 10.3389/fimmu.2022.886546. eCollection 2022.
5
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.免疫化疗增强了 CAR-T 细胞向肺部肿瘤的募集，并与检查点阻断联合使用时提高了抗肿瘤疗效。
Cancer Cell. 2021 Feb 8;39(2):193-208.e10. doi: 10.1016/j.ccell.2020.11.005. Epub 2020 Dec 24.
6
Determinants of response and resistance to CAR T cell therapy.嵌合抗原受体 T 细胞疗法的反应和耐药的决定因素。
Semin Cancer Biol. 2020 Oct;65:80-90. doi: 10.1016/j.semcancer.2019.11.004. Epub 2019 Nov 6.
7
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.嵌合抗原受体在癌症治疗设计中的局限性。
Cells. 2019 May 17;8(5):472. doi: 10.3390/cells8050472.
Zotero 插件